Drugs / SLC-3010
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05525247 | Dec 2022 → Aug 2025 | neoplasm | Selecxine | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07469683 | Mar 2026 → Oct 2029 expected | clear cell renal carcinoma | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLC-3010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07469683 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle” NCT05525247 ↗ |